{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:17:35Z","timestamp":1778023055843,"version":"3.51.4"},"reference-count":189,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>The incidence and prevalence of nontuberculous mycobacterial (NTM) disease are rising. This narrative review examines the evolution of NTM disease trends over the past four decades, in Canada and globally, encompassing changing epidemiology, shifting treatment paradigms, and emerging antimicrobial resistance patterns. Challenges to NTM treatment are explored, and novel and investigational therapies are summarized. Key themes include a significant increase in NTM disease incidence, temporal shifts in the dominant species causing human infections, evolution from single-drug to multi-drug treatment approaches, and growing concerns regarding macrolide resistance. The substantial challenges with treatment tolerability, effectiveness, and access are outlined. This review synthesizes data from multiple sources, including peer-reviewed literature, clinical trials, and public health databases, to provide a comprehensive understanding of the changing NTM disease landscape in Canada and more broadly. There is a need for expanded surveillance, continued innovation, and a multidisciplinary approach to NTM management.<\/jats:p>","DOI":"10.3390\/tropicalmed10120328","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:47:22Z","timestamp":1763984842000},"page":"328","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Review of the Canadian Nontuberculous Mycobacterial Disease Landscape\u2014Challenges and Opportunities"],"prefix":"10.3390","volume":"10","author":[{"given":"Sepideh","family":"Vahid","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Yan","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine, Faculty of Medicine and Dentistry, University of British Columbia, Vancouver, BC V5Z 1M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4244-6468","authenticated-orcid":false,"given":"Shannon Lee","family":"Turvey","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of British Columbia, Vancouver, BC V5Z 3J5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3201\/eid1911.130737","article-title":"Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998\u20132010","volume":"19","author":"Marras","year":"2013","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3201\/eid2311.170959","article-title":"Pulmonary versus Nonpulmonary Nontuberculous Mycobacteria, Ontario, Canada","volume":"23","author":"Brode","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","article-title":"Global Trends of Pulmonary Infections with Nontuberculous Mycobacteria: A Systematic Review","volume":"125","author":"Dahl","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ratnatunga, C.N., Lutzky, V.P., Kupz, A., Doolan, D.L., Reid, D.W., Field, M., Bell, S.C., Thomson, R.M., and Miles, J.J. (2020). The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00303"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1900250","DOI":"10.1183\/13993003.00250-2019","article-title":"Non-Tuberculous Mycobacterial Pulmonary Disease","volume":"54","author":"Cowman","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100244","DOI":"10.1016\/j.jctube.2021.100244","article-title":"Approach to the Diagnosis and Treatment of Non-Tuberculous Mycobacterial Disease","volume":"24","author":"Pennington","year":"2021","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100016","DOI":"10.1016\/j.clinme.2024.100016","article-title":"Extrapulmonary Nontuberculous Mycobacterial Infections: A Guide for the General Physician","volume":"24","author":"Malhotra","year":"2024","journal-title":"Clin. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Conyers, L.E., and Saunders, B.M. (2024). Treatment for Non-Tuberculous Mycobacteria: Challenges and Prospects. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1394220"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1164\/rccm.200905-0778OC","article-title":"Nontuberculous Pulmonary Mycobacteriosis in Denmark: Incidence and Prognostic Factors","volume":"181","author":"Thomsen","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3201\/eid1602.090675","article-title":"Increasing Incidence of Nontuberculous Mycobacteria, Taiwan, 2000\u20132008","volume":"16","author":"Lai","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Moore, J.E., Kruijshaar, M.E., Ormerod, L.P., Drobniewski, F., and Abubakar, I. (2010). Increasing Reports of Non-Tuberculous Mycobacteria in England, Wales and Northern Ireland, 1995\u20132006. BMC Public Health, 10.","DOI":"10.1186\/1471-2458-10-612"},{"key":"ref_13","first-page":"1069","article-title":"Rapid Increase of Non-Tuberculous Mycobacterial Lung Diseases at a Tertiary Referral Hospital in South Korea","volume":"14","author":"Park","year":"2010","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.idc.2010.04.008","article-title":"Nontuberculous Mycobacterial Lung Diseases","volume":"24","author":"Taiwo","year":"2010","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1513\/AnnalsATS.201605-353OC","article-title":"Increasing Prevalence Rate of Nontuberculous Mycobacteria Infections in Five States, 2008\u20132013","volume":"13","author":"Donohue","year":"2016","journal-title":"Ann. ATS"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1602109","DOI":"10.1183\/13993003.02109-2016","article-title":"Burden of Non-Tuberculous Mycobacterial Pulmonary Disease in Germany","volume":"49","author":"Diel","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1513\/AnnalsATS.201612-994OI","article-title":"Notification of Nontuberculous Mycobacteria: An Australian Perspective","volume":"14","author":"Thomson","year":"2017","journal-title":"Ann. ATS"},{"key":"ref_18","unstructured":"Queensland Health (2024, December 20). 2024. Notifiable Conditions Annual Reporting. Queensland Government Website, Available online: https:\/\/www.health.qld.gov.au\/clinical-practice\/guidelines-procedures\/diseases-infection\/surveillance\/reports\/notifiable\/annual."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Marshall, J.E., Mercaldo, R.A., Lipner, E.M., and Prevots, D.R. (2024). Nontuberculous Mycobacteria Testing and Culture Positivity in the United States. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09059-9"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.2147\/IDR.S368671","article-title":"Doubled Nontuberculous Mycobacteria Isolation as a Consequence of Changes in the Diagnosis Algorithm","volume":"15","author":"Chen","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Schiff, H.F., Jones, S., Achaiah, A., Pereira, A., Stait, G., and Green, B. (2019). Clinical Relevance of Non-Tuberculous Mycobacteria Isolated from Respiratory Specimens: Seven Year Experience in a UK Hospital. Sci. Rep., 9.","DOI":"10.1038\/s41598-018-37350-8"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of Human Pulmonary Infection with Nontuberculous Mycobacteria: A Review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin. Chest Med."},{"key":"ref_23","first-page":"19","article-title":"Isolation Prevalence of Pulmonary Nontuberculous Mycobacteria in Ontario in 2007","volume":"18","author":"Jamieson","year":"2011","journal-title":"Can. Respir. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccm.2023.07.001","article-title":"Environmental Sources and Transmission of Nontuberculous Mycobacteria","volume":"44","author":"Honda","year":"2023","journal-title":"Clin. Chest Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"00574","DOI":"10.1183\/23120541.00574-2020","article-title":"Nontuberculous Mycobacterial Pulmonary Disease: An Integrated Approach beyond Antibiotics","volume":"7","author":"Faverio","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1378\/chest.14-0974","article-title":"Natural Disasters and Nontuberculous Mycobacteria: A Recipe for Increased Disease?","volume":"147","author":"Honda","year":"2015","journal-title":"Chest"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"200299","DOI":"10.1183\/16000617.0299-2020","article-title":"The Respiratory Microbiome and Nontuberculous Mycobacteria: An Emerging Concern in Human Health","volume":"30","author":"Thornton","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.5588\/ijtld.14.0120","article-title":"The Epidemiologic Relationship between Tuberculosis and Non-Tuberculous Mycobacterial Disease: A Systematic Review","volume":"18","author":"Brode","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3201\/eid2907.230216","article-title":"Pulmonary Nontuberculous Mycobacteria, Ontario, Canada, 2020","volume":"29","author":"Marras","year":"2023","journal-title":"Emerg. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0272-5231(02)00019-9","article-title":"Epidemiology of Human Pulmonary Infection with Mycobacteria Nontuberculous","volume":"23","author":"Marras","year":"2002","journal-title":"Clin. Chest Med."},{"key":"ref_31","first-page":"319","article-title":"Incidence of Pulmonary Disease Caused by Mycobacteria Other than Tuberculosis in British Columbia","volume":"9","author":"Elwood","year":"2002","journal-title":"Can. Respir. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00408-010-9241-8","article-title":"Nontuberculous Mycobacterial Lung Infections in Ontario, Canada: Clinical and Microbiological Characteristics","volume":"188","author":"Marras","year":"2010","journal-title":"Lung"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1164\/rccm.200702-201OC","article-title":"Nontuberculous Mycobacterial Sensitization in the United States: National Trends over Three Decades","volume":"176","author":"Khan","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0038-1651491","article-title":"Epidemiology of Nontuberculous Mycobacteriosis","volume":"39","author":"Adjemian","year":"2018","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Armstrong, D.T., Eisemann, E., and Parrish, N. (2023). A Brief Update on Mycobacterial Taxonomy, 2020 to 2022. J. Clin. Microbiol., 61.","DOI":"10.1128\/jcm.00331-22"},{"key":"ref_36","unstructured":"Public Health Ontario (2024, November 14). Enhanced Epidemiological Summary: Nontuberculous Mycobacteria Disease in Ontario, January 1, 2020 to December 31, 2020. Published October 2022. Available online: https:\/\/www.publichealthontario.ca\/-\/media\/Documents\/N\/2022\/nontuberculous-mycobacteria-disease-ontario-2020.pdf?rev=83fc8c24d7b64fadb17352a53b5df0c4&sc_lang=en#:~:text=Among%20individuals%20tested%20for%20NTM,was%2019.0%20per%20100%2C000%20population."},{"key":"ref_37","first-page":"1086","article-title":"The Incidence of Pulmonary Non-Tuberculous Mycobacteria in British Columbia, Canada","volume":"13","author":"Rodrigues","year":"2009","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1183\/09031936.00149212","article-title":"The Geographic Diversity of Nontuberculous Mycobacteria Isolated from Pulmonary Samples: An NTM-NET Collaborative Study","volume":"42","author":"Hoefsloot","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jinf.2016.08.020","article-title":"The Prevalence of Non-Tuberculous Mycobacterial Infections in Mainland China: Systematic Review and Meta-Analysis","volume":"73","author":"Yu","year":"2016","journal-title":"J. Infect."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105967","DOI":"10.1016\/j.rmed.2020.105967","article-title":"Clinical Outcomes in Mycobacterium xenopi versus Mycobacterium avium Complex Pulmonary Disease: A Retrospective Matched Cohort Study","volume":"167","author":"Zaheen","year":"2020","journal-title":"Respir. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jiph.2020.12.027","article-title":"Prevalence and Speciation of Non-Tuberculous Mycobacteria among Pulmonary and Extrapulmonary Tuberculosis Suspects in South India","volume":"14","author":"Thangavelu","year":"2021","journal-title":"J. Infect. Public. Health"},{"key":"ref_42","unstructured":"(2014). Chapter 11: Nontuberculous Mycobacteria. Canadian Tuberculosis Standards, Tuberculosis Prevention and Control. [7th ed.]. Available online: https:\/\/www.phac-aspc.gc.ca\/tbpc-latb\/pubs\/tb-canada-7\/assets\/pdf\/tb-standards-tb-normes-ch11-eng.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bents, S.J., Mercaldo, R.A., Powell, C., Henkle, E., Marras, T.K., and Prevots, D.R. (2024). Nontuberculous Mycobacterial Pulmonary Disease (NTM PD) Incidence Trends in the United States, 2010\u20132019. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09965-y"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3947\/ic.2019.51.3.245","article-title":"Treatment of Extrapulmonary Nontuberculous Mycobacterial Diseases","volume":"51","author":"Wi","year":"2019","journal-title":"Infect. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2024.03.023","article-title":"Nationwide Increasing Incidence of Nontuberculous Mycobacterial Diseases Among Adults in Denmark","volume":"166","author":"Pedersen","year":"2024","journal-title":"Chest"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.mayocp.2012.06.029","article-title":"Increased Incidence of Cutaneous Nontuberculous Mycobacterial Infection, 1980 to 2009: A Population-Based Study","volume":"88","author":"Wentworth","year":"2013","journal-title":"Mayo Clin. Proc."},{"key":"ref_47","first-page":"S40","article-title":"Nontuberculous Mycobacteria in Children: A Changing Pattern","volume":"34","author":"Vu","year":"2005","journal-title":"J. Otolaryngol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/1203475418776945","article-title":"Cutaneous Nontuberculous Mycobacterial Infections in Alberta, Canada: An Epidemiologic Study and Review","volume":"22","author":"Sander","year":"2018","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"NP574","DOI":"10.1093\/asj\/sjae076","article-title":"The Price of Beauty: A Literature Review on Non-Tuberculous Mycobacteria Infection After Cosmetic Procedures","volume":"44","author":"Ren","year":"2024","journal-title":"Aesthetic Surg. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3201\/eid2806.220520","article-title":"Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012\u20132020","volume":"28","author":"McNamara","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e5479","DOI":"10.7717\/peerj.5479","article-title":"Epidemiology of and Risk Factors for Extrapulmonary Nontuberculous Mycobacterial Infections in Northeast Thailand","volume":"6","author":"Chetchotisakd","year":"2018","journal-title":"PeerJ"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.cmi.2021.07.017","article-title":"The Global Outbreak of Mycobacterium chimaera Infections in Cardiac Surgery\u2014A Systematic Review of Whole-Genome Sequencing Studies and Joint Analysis","volume":"27","author":"Schreiber","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(17)30324-9","article-title":"Global Outbreak of Severe Mycobacterium chimaera Disease after Cardiac Surgery: A Molecular Epidemiological Study","volume":"17","author":"Kohl","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"ofy018","DOI":"10.1093\/ofid\/ofy018","article-title":"Mycobacterium chimaera Infection After Aortic Valve Replacement Presenting With Aortic Dissection and Pseudoaneurysm","volume":"5","author":"Taylor","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cmi.2023.03.005","article-title":"Clinical Characteristics and Outcome of Mycobacterium chimaera Infections after Cardiac Surgery: Systematic Review and Meta-Analysis of 180 Heater-Cooler Unit-Associated Cases","volume":"29","author":"Wetzstein","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1128\/JCM.00435-13","article-title":"Prosthetic Valve Endocarditis and Bloodstream Infection Due to Mycobacterium chimaera","volume":"51","author":"Achermann","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.14745\/ccdr.v43i05a05","article-title":"Mycobacterium chimaera Infections in Post-Operative Patients Exposed to Heater-Cooler Devices: An Overview","volume":"43","author":"Ogunremi","year":"2017","journal-title":"Can. Commun. Dis. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.athoracsur.2017.01.115","article-title":"Mycobacterium chimaera Infection After Cardiac Surgery: First Canadian Outbreak","volume":"104","author":"Hamad","year":"2017","journal-title":"Ann. Thorac. Surg."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/cid\/ciy789","article-title":"Mycobacterium chimaera Infections Related to the Heater\u2013Cooler Unit Outbreak: A Guide to Diagnosis and Management","volume":"68","author":"Kasperbauer","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1164\/ajrccm\/142.4.940","article-title":"Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria","volume":"142","author":"Wallace","year":"1990","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1164\/ajrccm.156.2.atsstatement","article-title":"Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria","volume":"156","author":"Wallace","year":"1997","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM199608083350602","article-title":"A Comparison of Two Regimens for the Treatment of Mycobacterium avium Complex Bacteremia in AIDS: Rifabutin, Ethambutol, and Clarithromycin versus Rifampin, Ethambutol, Clofazimine, and Ciprofloxacin","volume":"335","author":"Shafran","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3346\/jkms.2005.20.6.913","article-title":"Diagnosis and Treatment of Nontuberculous Mycobacterial Pulmonary Diseases: A Korean Perspective","volume":"20","author":"Koh","year":"2005","journal-title":"J. Korean Med. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-Term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated with Regimens Including Clofazimine and\/or Rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"ref_65","unstructured":"National Institutes of Health, HIV Medicine Association, and Infectious Diseases Society of America (2025, November 01). Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-opportunistic-infection."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"102711","DOI":"10.1016\/j.jiph.2025.102711","article-title":"Two-Drug versus Three-Drug Regimens for Treating Mycobacterium avium Complex Infection: A Systematic Review and Meta-Analysis","volume":"18","author":"Nguyen","year":"2025","journal-title":"J. Infect. Public. Health"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"ofaf292","DOI":"10.1093\/ofid\/ofaf292","article-title":"Treatment Outcomes of Mycobacterium avium Complex Pulmonary Disease with a 2-Drug Daily Regimen Using Macrolide and Ethambutol","volume":"12","author":"Im","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S1473-3099(21)00586-7","article-title":"Consensus Management Recommendations for Less Common Non-Tuberculous Mycobacterial Pulmonary Diseases","volume":"22","author":"Lange","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4046\/trd.2024.0033","article-title":"Nonpharmacological Treatment for Nontuberculous Mycobacterial Pulmonary Disease","volume":"87","author":"Kim","year":"2024","journal-title":"Tuberc. Respir. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.21037\/jtd-22-410","article-title":"Ancillary Treatment of Patients with Lung Disease Due to Non-Tuberculous Mycobacteria: A Narrative Review","volume":"14","author":"Youssefnia","year":"2022","journal-title":"J. Thorac. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.00055509","article-title":"A Randomised Crossover Trial of Chest Physiotherapy in Non-Cystic Fibrosis Bronchiectasis","volume":"34","author":"Murray","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ccm.2023.07.005","article-title":"Investigation and Management of Bronchiectasis in Nontuberculous Mycobacterial Pulmonary Disease","volume":"44","author":"McShane","year":"2023","journal-title":"Clin. Chest Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"065","DOI":"10.23937\/2378-3516\/1410065","article-title":"Effects of Chest Physical Therapy in Patients with Non-Tuberculous Mycobacteria","volume":"4","author":"Basavaraj","year":"2017","journal-title":"Int. J. Respir. Pulm. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1802143","DOI":"10.1183\/13993003.02143-2018","article-title":"Outcomes of Hypertonic Saline Inhalation as a Treatment Modality in Nontuberculous Mycobacterial Pulmonary Disease","volume":"54","author":"Huiberts","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2019.03.014","article-title":"Long-Term Natural History of Non-Cavitary Nodular Bronchiectatic Nontuberculous Mycobacterial Pulmonary Disease","volume":"151","author":"Moon","year":"2019","journal-title":"Respir. Med."},{"key":"ref_76","first-page":"99","article-title":"Surgical Treatment of Non-Tuberculous Mycobacterial Lung Disease: Strike in Time","volume":"14","author":"Verhagen","year":"2010","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S1010-7940(01)01122-8","article-title":"Surgery for Mycobacterium avium Complex Lung Disease in the Clarithromycin Era","volume":"21","author":"Shiraishi","year":"2002","journal-title":"Eur. J. Cardio-Thorac. Surg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.athoracsur.2004.02.103","article-title":"Pneumonectomy for Nontuberculous Mycobacterial Infections","volume":"78","author":"Shiraishi","year":"2004","journal-title":"Ann. Thorac. Surg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11748-014-0402-1","article-title":"Surgical Treatment of Nontuberculous Mycobacterial Lung Disease","volume":"62","author":"Shiraishi","year":"2014","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Yu, J.A., Pomerantz, M., Bishop, A., Weyant, M.J., and Mitchell, J.D. (2011). Lady Windermere Revisited: Treatment with Thoracoscopic Lobectomy\/Segmentectomy for Right Middle Lobe and Lingular Bronchiectasis Associated with Non-Tuberculous Mycobacterial Disease. Eur. J. Cardio-Thorac. Surg.","DOI":"10.1016\/j.ejcts.2010.12.028"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Kang, H.K., Park, H.Y., Kim, D., Jeong, B.-H., Jeon, K., Cho, J.H., Kim, H.K., Choi, Y.S., Kim, J., and Koh, W.-J. (2015). Treatment Outcomes of Adjuvant Resectional Surgery for Nontuberculous Mycobacterial Lung Disease. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0823-1"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ccm.2023.06.013","article-title":"Surgical Resection in Nontuberculous Mycobacterial Pulmonary Disease","volume":"44","author":"Taylor","year":"2023","journal-title":"Clin. Chest Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1055\/s-0038-1651490","article-title":"Management of Extrapulmonary Nontuberculous Mycobacterial Infections","volume":"39","author":"Holt","year":"2018","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3109\/23744235.2015.1040445","article-title":"Nontuberculous Mycobacterial Osteomyelitis","volume":"47","author":"Bi","year":"2015","journal-title":"Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14787210.2025.2536837","article-title":"Clinical Treatment of Mycobacterial Prosthetic Joint Infections","volume":"23","author":"Esteban","year":"2025","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/DSS.0000000000001929","article-title":"Nontuberculous Mycobacterial Infections After Cosmetic Procedures: A Systematic Review and Management Algorithm","volume":"46","author":"Jabbour","year":"2020","journal-title":"Dermatol. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Kadota, N., Ishikawa, K., Kubono, Y., Konishi, K., Fujimaru, T., Ito, Y., Nagahama, M., Taki, F., Kawai, F., and Mori, N. (2024). Systematic Literature Review of the Diagnosis, Prognosis, and Treatment of Peritoneal Dialysis-Related Infection Caused by Nontuberculous Mycobacteria. BMC Nephrol., 25.","DOI":"10.1186\/s12882-024-03841-2"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1473-3099(12)70316-X","article-title":"Rapidly Growing Mycobacterial Bloodstream Infections","volume":"13","author":"Viola","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Veve, M.P., Kenney, R.M., Aljundi, A.M., Dierker, M.S., Athans, V., Shallal, A.B., and Patel, N. (2025). Multicenter, Retrospective Cohort Study of Antimycobacterial Treatment-Related Harms among Patients with Non-Tuberculosis Mycobacterium Infections in the United States. Antimicrob. Agents Chemother., 69.","DOI":"10.1128\/aac.01596-24"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ccm.2023.06.012","article-title":"Medications and Monitoring in Treatment of Nontuberculous Mycobacterial Pulmonary Disease","volume":"44","author":"Sawka","year":"2023","journal-title":"Clin. Chest Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.chest.2019.12.016","article-title":"Treatment Duration and Disease Recurrence Following the Successful Treatment of Patients with Mycobacterium avium Complex Lung Disease","volume":"157","author":"Furuuchi","year":"2020","journal-title":"Chest"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/AAC.04577-14","article-title":"Risk Factors for Recurrence after Successful Treatment of Mycobacterium avium Complex Lung Disease","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1602503","DOI":"10.1183\/13993003.02503-2016","article-title":"Outcomes of Mycobacterium avium Complex Lung Disease Based on Clinical Phenotype","volume":"50","author":"Koh","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1801038","DOI":"10.1183\/13993003.01038-2018","article-title":"The Second Recurrence of Mycobacterium avium Complex Lung Disease after Successful Treatment for First Recurrence","volume":"53","author":"Kwon","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1183\/09031936.00024008","article-title":"Long-Term Relapses after 12-Month Treatment for Mycobacterium kansasii Lung Disease","volume":"33","author":"Santin","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3201\/eid2808.220464","article-title":"Increasing and More Commonly Refractory Mycobacterium avium Pulmonary Disease, Toronto, Ontario, Canada","volume":"28","author":"Raats","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_97","first-page":"152","article-title":"A Retrospective Review of Non-Tuberculous Mycobacterium Treatment in Montreal","volume":"9","author":"Trudel","year":"2025","journal-title":"Can. J. Respir. Crit. Care Sleep Med."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Chancharoenthana, W., Kamolratanakul, S., Rotcheewaphan, S., Leelahavanichkul, A., and Schultz, M.J. (2025). Recent Advances in Immunopathogenesis and Clinical Practice: Mastering the Challenge-Managing of Non-Tuberculous Mycobacteria. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1554544"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Brown-Elliott, B.A., and Woods, G.L. (2019). Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria. J. Clin. Microbiol., 57.","DOI":"10.1128\/JCM.00834-19"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drup.2012.04.001","article-title":"Resistance Mechanisms and Drug Susceptibility Testing of Nontuberculous Mycobacteria","volume":"15","author":"Boeree","year":"2012","journal-title":"Drug Resist. Updates"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10156-006-0457-8","article-title":"Relationship between Clinical Efficacy of Treatment of Pulmonary Mycobacterium avium Complex Disease and Drug-Sensitivity Testing of Mycobacterium avium Complex Isolates","volume":"12","author":"Kobashi","year":"2006","journal-title":"J. Infect. Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and Molecular Analysis of Macrolide Resistance in Mycobacterium avium Complex Lung Disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann. ATS"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1164\/rccm.201003-0395OC","article-title":"Clinical Significance of Differentiation of Mycobacterium massiliense from Mycobacterium abscessus","volume":"183","author":"Koh","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/rccm.200905-0704OC","article-title":"Antibiotic Treatment of Mycobacterium abscessus Lung Disease: A Retrospective Analysis of 65 Patients","volume":"180","author":"Jeon","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In Vitro Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates","volume":"51","author":"Iakhiaeva","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Tsiolakkis, G., Liontos, A., Filippas-Ntekouan, S., Matzaras, R., Theodorou, E., Vardas, M., Vairaktari, G., Nikopoulou, A., and Christaki, E. (2023). Mycobacterium marinum: A Case-Based Narrative Review of Diagnosis and Management. Microorganisms, 11.","DOI":"10.3390\/microorganisms11071799"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An Official ATS\/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1128\/JCM.02022-10","article-title":"Case of Mycobacterium marinum Infection with Unusual Patterns of Susceptibility to Commonly Used Antibiotics","volume":"49","author":"Parrish","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Huh, H.J., Kim, S.-Y., Shim, H.J., Kim, D.H., Yoo, I.Y., Kang, O.-K., Ki, C.-S., Shin, S.Y., Jhun, B.W., and Shin, S.J. (2019). GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance. J. Clin. Microbiol., 57.","DOI":"10.1128\/JCM.00516-19"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/jac\/dkx021","article-title":"Evaluation of the New GenoType NTM-DR Kit for the Molecular Detection of Antimicrobial Resistance in Non-Tuberculous Mycobacteria","volume":"72","author":"Mougari","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Falkinham, J.O. (2018). Challenges of NTM Drug Development. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.01613"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1086\/514116","article-title":"A Randomized Evaluation of Ethambutol for Prevention of Relapse and Drug Resistance during Treatment of Mycobacterium avium Complex Bacteremia with Clarithromycin-Based Combination Therapy","volume":"176","author":"Sattler","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/infdis\/174.6.1218","article-title":"Effect of Ethambutol on Emergence of Clarithromycin-Resistant Mycobacterium avium Complex in the Beige Mouse Model","volume":"174","author":"Bermudez","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12931-019-1258-9","article-title":"Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium avium Complex Pulmonary Disease: A Systematic Review and Meta-Analysis","volume":"20","author":"Park","year":"2019","journal-title":"Respir. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society Consensus Recommendations for the Management of Non-Tuberculous Mycobacteria in Individuals with Cystic Fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society Guidelines for the Management of Adult Bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1128\/AAC.01027-15","article-title":"Assessing Primary and Secondary Resistance to Clarithromycin and Amikacin in Infections Due to Mycobacterium avium Complex Antimicrob","volume":"59","author":"Brossier","year":"2015","journal-title":"Agents Chemother."},{"key":"ref_121","unstructured":"(2025, April 20). Tuberculosis Physician Manual Section 12: Pulmonary Non-Tuberculous Mycobacteria (NTM). Available online: https:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Guidelines%20and%20Forms\/Guidelines%20and%20Manuals\/TB\/TB%20physician%20manual_section%2012.pdf."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Ren, W., Tan, Y., Ma, Z., Shang, Y., Li, S., Zhang, X., Wang, W., Yao, C., Yuan, J., and Li, L. (2024). In Vitro Susceptibility of Nontuberculous Mycobacteria in China. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09016-6"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1089\/mdr.2023.0024","article-title":"Antimicrobial Susceptibility Distributions of Clinical Isolates of Nontuberculous Mycobacteria in Israel","volume":"29","author":"Hershko","year":"2023","journal-title":"Microb. Drug Resist."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jgar.2021.02.024","article-title":"Antimicrobial Susceptibility Profiles of Mycobacterium abscessus Complex Isolates from Respiratory Specimens in Shanghai, China","volume":"25","author":"Guo","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41429-020-00392-0","article-title":"Comparison of Two-Drug Combinations, Amikacin\/Tigecycline\/Imipenem and Amikacin\/Tigecycline\/Clarithromycin against Mycobacteroides abscessus subsp. abscessus Using the in Vitro Time-Kill Assay","volume":"74","author":"Roman","year":"2021","journal-title":"J. Antibiot."},{"key":"ref_126","unstructured":"Woods, G.L., Brown-Elliott, B.A., Conville, P.S., Desmond, E.P., Hall, G.S., Lin, G., Pfyffer, G.E., Ridderhof, J.C., Siddiqi, S.H., and Wallace, R.J. (2025, November 14). Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544374\/."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Kim, S.-Y., Kim, D.H., Moon, S.M., Song, J.Y., Huh, H.J., Lee, N.Y., Shin, S.J., Koh, W.-J., and Jhun, B.W. (2021). Association between 16S rRNA Gene Mutations and Susceptibility to Amikacin in Mycobacterium avium Complex and Mycobacterium abscessus Clinical Isolates. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-85721-5"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Ka Lip, C., Go, J., Binte Abu Bakar, N.A., Octavia, S., Pin Lin, R.T., and Teo, J.W.P. (2025). Whole-Genome Phylogenetic Analysis of Mycobacterium avium Complex from Clinical Respiratory Samples. Microbiol. Spectr., 13.","DOI":"10.1128\/spectrum.01600-24"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez Mart\u00ednez, A., Aguilera, M., Tarri\u00f1o, M., Alberola, A., Reguera, J.A., Sampedro, A., Navarro, J.M., and Rodr\u00edguez Granger, J. (2024). Susceptibility Patterns in Clinical Isolates of Mycobacterium avium Complex from a Hospital in Southern Spain. Microorganisms, 12.","DOI":"10.3390\/microorganisms12122613"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Sirichoat, A., Kaewprasert, O., Hinwan, Y., and Faksri, K. (2023). Phenotypic Drug-Susceptibility Profiles and Genetic Analysis Based on Whole-Genome Sequencing of Mycobacterium avium Complex Isolates in Thailand. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0294677"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Minuk, L.M., Brode, S.K., Mehrabi, M., Sharma, M.K., Stobart, M., Soualhine, H., and Marras, T.K. (2024). Phenotypic Amikacin Resistance May Not Indicate Poor Response to Amikacin in Mycobacterium avium Complex Pulmonary Disease. Antimicrob. Agents Chemother.","DOI":"10.1128\/aac.00084-24"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Hunkins, J.-J., de-Moura, V.-C.-N., Eddy, J.-J., Daley, C.-L., and Khare, R. (2023). In Vitro Susceptibility Patterns for Rapidly Growing Nontuberculous Mycobacteria in the United States. Diagn. Microbiol. Infect. Dis., 105.","DOI":"10.1016\/j.diagmicrobio.2022.115882"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/JCM.02260-12","article-title":"Comparative Drug Resistance of Mycobacterium Abscessus and M. Chelonae Isolates from Patients with and without Cystic Fibrosis in the United Kingdom","volume":"51","author":"Broda","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Saxena, S., Spaink, H.P., and Forn-Cun\u00ed, G. (2021). Drug Resistance in Nontuberculous Mycobacteria: Mechanisms and Models. Biology, 10.","DOI":"10.3390\/biology10020096"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.jfma.2020.05.018","article-title":"Treatment of Pulmonary Disease Caused by Mycobacterium kansasii","volume":"119","author":"Huang","year":"2020","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Guo, Y., Cao, Y., Liu, H., Yang, J., Wang, W., Wang, B., Li, M., and Yu, F. (2022). Clinical and Microbiological Characteristics of Mycobacterium kansasii Pulmonary Infections in China. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.01475-21"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"100463","DOI":"10.1016\/j.jctube.2024.100463","article-title":"Efficacy and Treatment Outcome of Infected Patients with Pulmonary Mycobacterium kansasii: A Systematic Review","volume":"36","author":"Andalibi","year":"2024","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Moon, S.M., Kim, S.-Y., Kim, D.H., Huh, H.J., Lee, N.Y., and Jhun, B.W. (2022). Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease. Antimicrob. Agents Chemother., 66.","DOI":"10.1128\/aac.02027-21"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Kim, D.H., Kim, S.-Y., Huh, H.J., Lee, N.Y., Koh, W.-J., and Jhun, B.W. (2021b). In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, Including Macrolide- and Amikacin-Resistant Clinical Isolates. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.02611-20"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Hajikhani, B., Nasiri, M.J., Adkinson, B.C., Azimi, T., Khalili, F., Goudarzi, M., Dadashi, M., Murthi, M., and Mirsaeidi, M. (2021). Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment of Mycobacterium avium Complex: A Meta-Analysis Study. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.693369"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Thapa, J., Chizimu, J.Y., Kitamura, S., Akapelwa, M.L., Suwanthada, P., Miura, N., Toyting, J., Nishimura, T., Hasegawa, N., and Nishiuchi, Y. (2023). Characterization of DNA Gyrase Activity and Elucidation of the Impact of Amino Acid Substitution in GyrA on Fluoroquinolone Resistance in Mycobacterium avium. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.05088-22"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1128\/AAC.02281-12","article-title":"Treatment of Refractory Mycobacterium avium Complex Lung Disease with a Moxifloxacin-Containing Regimen","volume":"57","author":"Koh","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40249-021-00844-1","article-title":"Nontuberculous Mycobacteria in China: Incidence and Antimicrobial Resistance Spectrum from a Nationwide Survey","volume":"10","author":"Liu","year":"2021","journal-title":"Infect. Dis. Poverty"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jgar.2021.06.002","article-title":"Clofazimine Susceptibility Testing of Mycobacterium avium Complex and Mycobacterium abscessus: A Meta-Analysis Study","volume":"26","author":"Hajikhani","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.chest.2020.07.040","article-title":"Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome","volume":"159","author":"Kwak","year":"2021","journal-title":"Chest"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jac\/dkad372","article-title":"Bedaquiline for Treatment of Non-Tuberculous Mycobacteria (NTM): A Systematic Review and Meta-Analysis","volume":"79","author":"Omar","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmi.2023.02.007","article-title":"Towards Clinical Breakpoints for Non-Tuberculous Mycobacteria\u2014Determination of Epidemiological Cut off Values for the Mycobacterium avium Complex and Mycobacterium abscessus Using Broth Microdilution","volume":"29","author":"Maurer","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_148","unstructured":"Campbell, A., and Pawa, J. (2018). Exploring Specialized Care for Non-Tuberculous Mycobacterial (NTM) Patients in British Columbia (BC), 2018. British Columbia Centre for Disease Control, Provincial Health Services Authority. Available online: https:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Statistics%20and%20Research\/Statistics%20and%20Reports\/TB\/TB_NTM%20report.pdf."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.mayocp.2018.12.011","article-title":"Pharmacotherapy Approaches in Nontuberculous Mycobacteria Infections","volume":"94","author":"Shulha","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1093\/cid\/ciae421","article-title":"Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects","volume":"79","author":"Nguyen","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside Toxicity: Daily versus Thrice-Weekly Dosing for Treatment of Mycobacterial Diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1128\/AAC.02282-15","article-title":"Amikacin Pharmacokinetics\/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1093\/cid\/ciaa1361","article-title":"Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey","volume":"73","author":"Aliberti","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.201408-1545OC","article-title":"Intermittent Antibiotic Therapy for Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease","volume":"191","author":"Jeong","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.5588\/ijtld.18.0171","article-title":"Adverse Reactions Associated with Long-Term Drug Administration in Mycobacterium avium Complex Lung Disease","volume":"22","author":"Kamii","year":"2018","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1183\/09031936.00055010","article-title":"The Cost of Medical Management of Pulmonary Nontuberculous Mycobacterial Disease in Ontario, Canada","volume":"37","author":"Leber","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Goring, S.M., Wilson, J.B., Risebrough, N.R., Gallagher, J., Carroll, S., Heap, K.J., Obradovic, M., Loebinger, M.R., and Diel, R. (2018). The Cost of Mycobacterium Avium Complex Lung Disease in Canada, France, Germany, and the United Kingdom: A Nationally Representative Observational Study. BMC Health Serv. Res., 18.","DOI":"10.1186\/s12913-018-3489-8"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3201\/eid2609.190524","article-title":"Costs Associated with Nontuberculous Mycobacteria Infection, Ontario, Canada, 2001\u20132012","volume":"26","author":"Ramsay","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/17476348.2021.1887734","article-title":"A Multidisciplinary Approach to the Management of Nontuberculous Mycobacterial Lung Disease: A Clinical Perspective","volume":"15","author":"Ali","year":"2021","journal-title":"Expert. Rev. Respir. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"100909","DOI":"10.1016\/S2666-5247(24)00149-6","article-title":"Bedaquiline: What Might the Future Hold?","volume":"5","author":"Shaw","year":"2024","journal-title":"Lancet Microbe"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Kurbatfinski, N., Hill, P.J., Tobin, N., Kramer, C.N., Wickham, J., Goodman, S.D., Hall-Stoodley, L., and Bakaletz, L.O. (2023). Disruption of Nontuberculous Mycobacteria Biofilms Induces a Highly Vulnerable to Antibiotic Killing Phenotype. Biofilm, 6.","DOI":"10.1016\/j.bioflm.2023.100166"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Egea, M.-C., Akir, A., and Esteban, J. (2023). Mycobacterium Biofilms. Biofilm, 5.","DOI":"10.1016\/j.bioflm.2023.100107"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Kaur, P., Krishnamurthy, R.V., Shandil, R.K., Mohan, R., and Narayanan, S. (2023). A Novel Inhibitor against the Biofilms of Non-Tuberculous Mycobacteria. Pathogens, 13.","DOI":"10.3390\/pathogens13010040"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Esteban, J., and Garc\u00eda-Coca, M. (2018). Mycobacterium Biofilms. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.02651"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1080\/14656566.2024.2412250","article-title":"New Antibiofilm Strategies for the Management of Nontuberculous Mycobacteria Diseases","volume":"25","author":"Esteban","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12931-022-02299-w","article-title":"Meeting the Challenges of NTM-PD from the Perspective of the Organism and the Disease Process: Innovations in Drug Development and Delivery","volume":"23","author":"Obradovic","year":"2022","journal-title":"Respir. Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"A3168","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A3168","article-title":"A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adults With Nontuberculous Mycobacterial Pulmonary Disease (NTM PD) Caused by Mycobacterium abscessus Complex (MABc)","volume":"211","author":"Winthrop","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1513\/AnnalsATS.202306-532OC","article-title":"OPTIMA: An Open-Label, Noncomparative Pilot Trial of Inhaled Molgramostim in Pulmonary Nontuberculous Mycobacterial Infection","volume":"21","author":"Thomson","year":"2024","journal-title":"Ann. ATS"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"20499361251339300","DOI":"10.1177\/20499361251339300","article-title":"Recombinant Interleukin-7 Treatment of Refractory Mycobacterium avium Complex Lung Disease (IMPULSE-7): A Pilot Phase II, Single-Center, Randomized, Clinical Trial","volume":"12","author":"Spec","year":"2025","journal-title":"Ther. Adv. Infect."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Daley, C.L., Chalmers, J.D., Flume, P.A., Griffith, D.E., Hasegawa, N., Morimoto, K., Winthrop, K.L., Sheu, C.-C., Hassan, M., and Nevoret, M.-L. (2024). Microbiologic Outcomes From a Randomized, Double-Blind Trial of Amikacin Liposome Inhalation Suspension in Adults With Newly Diagnosed or Recurrent Mycobacterium avium Complex Lung Disease: The ARISE Study. A16. NTM with a Side of Bronchiectasis, American Thoracic Society.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A1033"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"107069","DOI":"10.1016\/j.rmed.2022.107069","article-title":"Inhaled Nitric Oxide for Adults with Pulmonary Non-Tuberculous Mycobacterial Infection","volume":"206","author":"Flume","year":"2023","journal-title":"Respir. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/jac\/dkae309","article-title":"A Loading Dose of Clofazimine to Rapidly Achieve Steady-State-like Concentrations in Patients with Nontuberculous Mycobacterial Disease","volume":"79","author":"Stemkens","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Zheng, L., Qi, X., Zhang, W., Wang, H., Fu, L., Wang, B., Chen, X., Chen, X., and Lu, Y. (2023). Efficacy of PBTZ169 and Pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB\/c Mice Models. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1115530"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Makarov, V., and Miku\u0161ov\u00e1, K. (2020). Development of Macozinone for TB Treatment: An Update. Appl. Sci., 10.","DOI":"10.3390\/app10072269"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Rimal, B., Howe, R.A., Panthi, C.M., Wang, W., and Lamichhane, G. (2024). Oral Oxaborole MRX-5 Exhibits Efficacy against Pulmonary Mycobacterium abscessus in Mouse. Antimicrob. Agents Chemother., 68.","DOI":"10.1128\/aac.01351-24"},{"key":"ref_176","unstructured":"MicuRx Newsletter (2025, May 20). MicuRx\u2019s Self-Developed MRX-5 for NTM Infection Clinical Trial Application Approved. Available online: https:\/\/www.micurx.com\/2161.html."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Mediaas, S.D., Haug, M., Louet, C., Wahl, S.G.F., Gidon, A., and Flo, T.H. (2024). Metformin Improves Mycobacterium avium Infection by Strengthening Macrophage Antimicrobial Functions. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1463224"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Mercaldo, R., Fennelly, K.P., Honda, S., Frankland, T.B., Daida, Y.G., and Prevots, R. (2024). Metformin Use Reduces the Risk of Nontuberculous Mycobacteria Infection: Results From a Population-Based Cohort in Hawaii, USA. C68. NTM: Challenging Science and Cases, American Thoracic Society.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A6302"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Huang, Z., Luo, W., Xu, D., Guo, F., Yang, M., Zhu, Y., Shen, L., Chen, S., Tang, D., and Li, L. (2022). Discovery and Preclinical Profile of Sudapyridine (WX-081), a Novel Anti-Tuberculosis Agent. Bioorganic Med. Chem. Lett., 71.","DOI":"10.1016\/j.bmcl.2022.128824"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Zheng, L., Wang, H., Qi, X., Zhang, W., Wang, B., Fu, L., Chen, X., Chen, X., and Lu, Y. (2024). Sudapyridine (WX-081) Antibacterial Activity against Mycobacterium avium, Mycobacterium abscessus, and Mycobacterium chelonae In Vitro and In Vivo. mSphere, 9.","DOI":"10.1128\/msphere.00518-23"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Fan, J., Tan, Z., He, S., Li, A., Jia, Y., Li, J., Zhang, Z., Li, B., and Chu, H. (2024). TBAJ-587, a Novel Diarylquinoline, Is Active against Mycobacterium abscessus. Antimicrob. Agents Chemother., 68.","DOI":"10.1128\/aac.00945-24"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/jac\/dkae288","article-title":"Dual \u03b2-Lactams for the Treatment of Mycobacterium abscessus: A Review of the Evidence and a Call to Act against an Antibiotic Nightmare","volume":"79","author":"Longo","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.cmi.2024.03.019","article-title":"Dual \u03b2-Lactam Therapy to Improve Treatment Outcome in Mycobacterium abscessus Disease","volume":"30","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Guo, Q., Xu, L., Tan, F., Zhang, Y., Fan, J., Wang, X., Zhang, Z., Li, B., and Chu, H. (2021). A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium Abscessus Activity In Vitro. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.00889-21"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Gao, S., Nie, W., Liu, L., Su, L., You, Y., Geng, R., and Chu, N. (2023). Antibacterial Activity of the Novel Oxazolidinone Contezolid (MRX-I) against Mycobacterium abscessus. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1225341"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jac\/dkz511","article-title":"Is There a Role for Tedizolid in the Treatment of Non-Tuberculous Mycobacterial Disease?","volume":"75","author":"Ruth","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Tang, Y.W., Cheng, B., Yeoh, S.F., Lin, R.T.P., and Teo, J.W.P. (2018). Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates\u2014An in Vitro Characterization Study. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.02095"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"ofab093","DOI":"10.1093\/ofid\/ofab093","article-title":"Tedizolid vs. Linezolid for the Treatment of Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients","volume":"8","author":"Poon","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Koomanan, N., Yvonne Zhou, P., Andrea Kwa, L.H., and Chung, S.J. (2025). P-799. Eravacycline in the Management of Nontuberculous Mycobacteria (NTM) Infections: A Single-Centre Experience. Open Forum Infect. Dis., 12.","DOI":"10.1093\/ofid\/ofae631.991"}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/10\/12\/328\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:44:30Z","timestamp":1763988270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/10\/12\/328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":189,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["tropicalmed10120328"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed10120328","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]}}}